Latest Apolipoproteins Stories
MUTATIONS IN APOA5 GENE FOUND TO INCREASE BLOOD TRIGLYCERIDES AND HEART ATTACK RISK CAMBRIDGE, Mass., Dec.
Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events following Myocardial Infarction KING OF
CSL112 Represents a Promising Investigational Therapy That May Fill a Void in Reducing Early Recurrent Cardiovascular Events in Patients Who Have Suffered a Heart Attack KING OF PRUSSIA, Pa.,
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
GIA announces the release of a comprehensive global report on Cholesterol Testing markets.
Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain
CARLSBAD, Calif., July 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Maintaining hippocampus volume is key to delaying cognitive decline and onset of dementia symptoms in those with genetic risk for Alzheimer's
"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31, 2014 /PRNewswire/ - Resverlogix
Data demonstrates that the NMR LipoProfile® test provides clinically reliable information to help reduce cardiovascular events, especially in patients with diabetes and those on statin therapy WASHINGTON,
- To give a box on the ear to.